SECTION 1. Notwithstanding any special or general law to the contrary, the department of public health and the board of registration in medicine shall develop, or provide for, a healthcare provider education campaign that encourages the adoption of all Food and Drug Administration, FDA, approved medications for the treatment of opioid use disorder. The goal of the campaign is to increase the number of providers offering all FDA-approved medications, directly or by referral, along with counseling and other appropriate support services. The training shall include, but not be limited to guidelines and best practices for: assessment; toxicology screens; treatment plans, including counseling frequency and type; detoxification/withdrawal management and induction care coordination; appropriate length of treatment; and relapse prevention. The training developed or provided shall be accepted by the board as up to 2 continuing professional development credits.
SECTION 2. Notwithstanding any special or general law to the contrary, the department of public health and the bureau of substance abuse services shall establish a peer mentoring program that supplements the healthcare provider educational campaign by providing a network for peer-to-peer trainings, materials, and prescriber and clinical team support. Peer mentors should have strong credentials, expertise and clinical experience with all FDA-approved medications for the treatment of opioid use disorder. Mentors shall provide coaching for providers licensed or certified by the department of public health. The department shall prioritize the efforts of the peer mentor program for providers serving geographic areas of the commonwealth identified by the department where access to medication assisted treatment is limited. The training program shall include, but not be limited to the following criteria: patient eligibility, optimal selection criteria, placement matching, patient engagement, team coaching and coordination, withdrawal management and induction, dosing and administration, clinical evaluation and laboratory monitoring, side effect management, co-occurring disorders management, drug-drug interactions, treatment retention, managed care interactions, and termination of medication.
SECTION 3. There shall be a grant program established to support providers who demonstrate the ability to offer all FDA-approved medications, along with counseling and other supports, directly or by referral. Providers who complete the waiver process and the educational programming on all FDA approved medications will be eligible to apply for funding to add a staff person(s) to support the expanded services.
SECTION 4. The department of public health shall create an inventory of health care providers treating patients with medications to measure adoption of offering all FDA-approved treatment options across the commonwealth. They shall also submit a report to the house and senate committees on ways and means and the joint committee on mental health and substance use, and recovery on the number of providers trained and any identified obstacles to expanding the number of providers offering all FDA-approved medications by January 1, 2023.
The information contained in this website is for general information purposes only. The General Court provides this information as a public service and while we endeavor to keep the data accurate and current to the best of our ability, we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, reliability, suitability or availability with respect to the website or the information contained on the website for any purpose. Any reliance you place on such information is therefore strictly at your own risk.